See What HealthDay Can Do For You
Contact Us

MicroRNA Expression Tied to Prostate Cancer Recurrence

Tumor volume and microRNA-100 independently related to biochemical recurrence of tumors

THURSDAY, March 10 (HealthDay News) -- Biochemical recurrence of localized prostate cancer in patients treated with radical prostatectomy is linked to high levels of microRNAs (miRNAs), according to a study published in the March issue of The Journal of Urology.

Katia R.M. Leite, M.D., Ph.D., from Genoa Biotechnology in São Paulo, Brazil, and colleagues analyzed the correlation between miRNA expression and progress of prostate cancer by studying frozen specimens from 49 patients treated with radical prostatectomy for prostate cancer. A quantitative reverse transcriptase-polymerase chain reaction was used to determine the expression of 14 miRNAs in 21 men with biochemical recurrence (prostate-specific antigen, >0.2 ng/mL) and 28 without. All specimens were analyzed for tumor volume, pathological staging, and Gleason score. Benign prostate prostatic hyperplasia tissue samples were used as controls.

The investigators found that high levels of four miRNAs were linked to tumor recurrence. The risk of recurrence for high expression levels of miR-100, miR-145, miR-191, and miR-let7c, was 3.0, 3.3, 2.7, and 3.4, respectively. Tumor volume and miR-100 were independently linked with biochemical recurrence of tumor.

"Our results show that miR-100 expression greater than 39.4 together with tumor volume are independently related to biochemical recurrence in patients treated with radical prostatectomy for prostate cancer," the authors write.

Full Text

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.